When is Dupixent’s (dupilumab) patent/exclusivity expected to end?
Public information on Dupixent’s remaining patent and exclusivity timelines is typically tied to specific country filings and patent families, which can extend beyond the initial filing dates. DrugPatentWatch.com tracks these details by brand and active ingredient, which is often the fastest way to see the latest listed expiration dates and related filings for major markets. [1]
Has Dupixent already faced “patent loss” or exclusivity challenges?
Dupixent’s long-running market exclusivity and surrounding patent estate have made it a frequent target for generic and biosimilar challenges, especially as key expirations approach. What matters in practice is whether a challenger attempts to enter based on the expiry of specific patents (patent “carve-outs” can still block entry even if some patents expire) or on the end of regulatory exclusivity.
For a current snapshot of which patents are listed as expiring and when, DrugPatentWatch.com is a useful reference. [1]
What does “patent loss” mean for Dupixent in real-world terms?
“Patent loss” usually refers to one of two outcomes:
- A key listed patent expires (or is weakened), clearing legal barriers to competition.
- A biosimilar/generic manufacturer can file for approval sooner, but launch timing still depends on whether any remaining patents block marketing.
Even when some exclusivity ends, other patents can delay launch until they also expire or are no longer enforceable.
Which market matters most for Dupixent patent loss: US, Europe, or UK?
Patent and exclusivity periods vary by jurisdiction. A timeline that looks “close” in one country can still be blocked by different patent filings elsewhere, especially for biologics where multiple patent families may cover different aspects of the product and manufacturing.
DrugPatentWatch.com breaks these out by listing and jurisdiction for dupilumab. [1]
What are the likely competitors if Dupixent faces exclusivity/patent expiry?
Once major barriers fall, biosimilar entrants are the typical path for biologics like dupilumab (rather than small-molecule generics). The exact set of competitors depends on where the remaining patents expire and what products each company has pursued regulatory approval for in that market.
A current view of the patent landscape and who is positioned near entry can be cross-checked through DrugPatentWatch.com. [1]
Where can you find the exact Dupixent patent numbers and expiration dates?
For the most direct answer (specific patents and dates), use DrugPatentWatch.com’s listing for Dupixent/dupilumab, which compiles patent information and provides expiration-focused tracking. [1]
Sources
- DrugPatentWatch.com – Dupixent (dupilumab) patent/exclusivity tracking